Summary.-Serum sialyl transferase (SST) was measured in 49 female patients with advanced breast cancer and 60 female controls. The mean SST level was significantly raised in patients with advanced breast cancer. There was no correlation between specific sites, or numbers of sites of metastatic disease and SST levels. The patients with advanced breast cancer were all treated with chemotherapy; in 13/21 responders there was a significant fall in SST and in 2 responders a significant rise in SST. The 6 patients who died after one course of chemotherapy had a significantly higher mean SST than those surviving longer. SST appears to lack sufficient specificity to be of practical value as a marker of response in patients with breast cancer treated by chemotherapy, though constant measurement of changes in SST may be of use in monitoring drug response. Raised SST at the commencement of chemotherapy may signify poor prognosis.
THE GLYCOSYL TRANSFERASES are a group of enzymes involved in glycoprotein synthesis; they catalyse addition of specific monosaccharides to the growing glycoprotein molecule. There may be alterations in the composition of the various cell-surface glycoproteins in malignancy (Van Beek et al., 1]973) and, associated with this, elevations in the different glycosyl transferases found in the sera of patients with neoplastic disease. Plasma fucosyl transferase (Khilanani et al., 1 978) and galactosyl transferase levels (Paone et al., 1978) have been shown to be increased in some malignancies. More particularly, serum and plasma sialyl transferase has been found to be raised in patients with breast (Ganzinger & Moser, 1979) and other cancers (Dao et al., 1980; Ganzinger & Deutsch, 1980 (Hayward et al., 1977) .
Controls.-Sera were collected from female volunteers aged 35 + years as part of a larger study of the aetiology of breast cancer (Farew^ell et al., 1978) . All volunteers had a clinical examination and mammographv to exclude breast pathology.
Ser um1 collection.-Blood samples from patients and controls were collected. allowed to stand for 1 h, centrifuged at 800 g and the resultant serum wxias stored at -20°C until assayed. Serum was collected immediately before each cycle of chemotherapy. Sera from controls were assayed within 1 month of collection, whilst sera from patients wNere stored for periods of 1 to 24 months before assay. There were no differences in baseline enzyme activity between patients wNhose sera w\as assayed within 1 month of collection (n= 13). from 1 to 6 months of collection (n= 16) or for longer than this period (n=20). In addition, in a sample assayed on 40 occasions over 2 years, the coefficient of variation wAas 5%. These results suggest that, storage at -20°C for up to 2 years does not significantlv alter serum enzyme activity.
Statistical methods. 
Baseline values
The mean baseline serum sialyl transferase (SST) level in patients with advanced breast cancer was higher than in controls (Table I ). In addition, mean baseline levels are shown for each categorv of response to chemotherapy. The 6 patients who died after the first course of chemotherapy had a mean SST of 406 + 76 209. Table III shows the mean SST according to individual disease sites and numbers of sites involved at the commencement of chemotherapy. There was no clear relationship between SST levels and any site, or numbers of sites, of disease involvement.
Serial values
Measurement of SST at any given time (e.g. 3-6 weeks) after the initiation of treatment had no prognostic value. However, if the pretreatment value for a particular patient was used as a reference point, then changes in SST were weakly related to response. If the SST level was above the baseline 6 weeks after treatment, the response + no-change rate w%ias If the SST levels were below the pretreatment value at both 3 and 6 weeks after treatment, the response+no-change rate was 12/12 patients. If SST was raised both times, the response + nochange rate was 6/11 patients (X2=6X96, P < 0005). As no data were available on the changes in serial SST with time in patients with untreated metastatic disease, a significant change in SST was arbitrarily regarded as >s.d. of controls (viz. > 41 ct/min/mg protein/h). Table IV shows the relationship between the lowest value of SST and response category. In 13/21 responders there was a fall in SST in remission, and in 8/21 responders this was a fall of >2 s.d.
(viz. > 82 ct/min/mg protein/h), whilst in the non-responders there was a fall in 4/13. and in only 1/13 was this fall > 2 s.d. These differences are not significant. (Ganzinger & Moser, 1979; Dao et al., 1980; Kessel & Allen, 1975) , and our results confirm these findings. Unlike other reports (Dao et al., 1980; Henderson & Kessel, 1977) , there was no clear relationship between SST levels and sites or bulk of metastic disease.
It has been shown that surgical removal of tumour tissue will lead to a fall in SST, and similarly, after ablative endocrine therapy, objective regression of disease is accompanied by a fall in SST (Dao et al., 1980) . In this study it was found that in 11 patients with advanced breast cancer treated with chemotherapy, significant falls in SST occurred in all 3 responders and significant rises in all 4 patients with progressive disease. Similar results have been shown by others (Ganzinger & Moser, 1979) . Our results also show a fall in SST is often associated with successful chemotherapy, and that a fall may precede clinical evidence of response. One contradictory finding that emerges from this study is that although no relationship between SST and bulk of disease has been demonstrated, changes in level do reflect response to treatment and, presumably, change in tumour burden. All patients in this study had extensive disease, even if only one site was involved, and there is some evidence from animal models that there is a direct relationship between sialyl transferase activity and tumour burden, but only up to a certain threshold, above which increases in tumour burden are not reflected by increases in SST activity (Evans et al., 1980) . It is possible that the existence of a similar phenomenon in human breast cancer may explain this apparent discrepancy.
Constant and accurate measurement of changes in SST may be of some use in monitoring response to chemotherapy, but both false-negative results (a rise in SST associated with a response to chemotherapy) and false-positive results (a fall in SST, associated with disease progression) occur. In view of this lack of specificity we are investigating the possibility that a tumour-associated isoenzyme of sialyl transferase may be a more useful marker for the follow-up of patients with breast cancer (Kessel et al., 1981) . 
